<DOC>
	<DOCNO>NCT02155504</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability pharmacokinetics ( PK ) single ascend oral dos ASP3700 healthy male subject . This study also explore effect itraconazole ( another drug ) PK ASP3700 , well evaluate safety tolerability ASP3700 alone combination itraconazole healthy male subject .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability Pharmacokinetics ASP3700 Healthy Male Subjects</brief_title>
	<detailed_description>This study consist 2 part : Part 1 single ascend dose study subject receive either ASP3700 matching placebo ; Part 2 drug-drug interaction ( DDI ) open-label , crossover study comprise 1 sequence 2 investigational period subject receive ASP3700 alone combination itraconazole .</detailed_description>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Subject body mass index range 18.5 30.0 kg/m2 . The subject weigh least 50 kg . Subject female spouse/partners childbearing potential must use highly effective contraception consist 2 form birth control ( 1 must barrier method ) start screen continue throughout clinical study period 90 day final study drug administration . Subject must donate sperm start screen throughout clinical study period 90 day final study drug administration . Subject know suspected hypersensitivity ASP3700 ( part 1 2 ) itraconazole ( part 2 ) significant adverse reaction historical cannabinoid use component formulation use . Subject liver function test ( aspartate aminotransferase [ AST ] , alanine aminotransferase [ ALT ] , alkaline phosphatase , gammaglutamyl transaminase , total bilirubin [ TBL ] ) upper limit normal ( ULN ) . In case assessment may repeat ( upon admission clinical unit ) . Subject history suicide attempt suicidal behavior . Any recent suicidal ideation within last 3 month significant risk commit suicide , judge Investigator use CSSRS ( level 4 5 ) screen upon admission clinical unit . Subject clinically significant abnormality follow Investigator 's review physical examination , ECG clinical study protocoldefined clinical laboratory test screen upon admission clinical unit . Subject pulse rate &lt; 40 &gt; 90 beat per minute ; mean SBP &gt; 140 mmHg ; mean DBP &gt; 90 mmHg ( vital sign measurement take triplicate subject rest supine position 5 minute ; pulse rate measure automatically ) upon admission clinical unit . Subject mean correct QT interval use Fridericia 's formula ( QTcF ) interval &gt; 430 ms day 1 . If mean QTcF exceed limit , 1 additional triplicate ECG take . Subject history smoking 10 cigarette ( equivalent amount tobacco ) per day within 3 month prior admission clinical unit . Subject history drink 21 unit alcohol per week ( 1 unit = 10 g pure alcohol = 250 mL beer [ 5 % ] 35 mL spirit [ 35 % ] 100 mL wine [ 12 % ] ) within 3 month prior admission clinical unit . Subject consume grapefruit , grapefruitcontaining product Seville orangecontaining product within 72 hour prior admission clinical unit .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>ASP3700</keyword>
	<keyword>Itraconazole</keyword>
	<keyword>Drug-drug interaction</keyword>
</DOC>